Dermatology Reports最新文献

{"title":"Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature.","authors":"Stefano Veraldi,&nbsp;Vinicio Boneschi,&nbsp;Marco Cusini,&nbsp;Carlo Alberto Maronese","doi":"10.4081/dr.2022.9503","DOIUrl":"https://doi.org/10.4081/dr.2022.9503","url":null,"abstract":"<p><p>Only a few cases of pityriasis rosea (PR)/pityriasis rosea-like eruption (PRLE) after anti-SARS-CoV-2 vaccination have been reported. In the period May 2021- February 2022 we observed five cases of clinically typical PR that appeared 2 to 3 weeks after anti-SARS-CoV-2 vaccination with BNT162b2 (3 patients) or mRNA- 1273 (2 patients). In 4 patients PR appeared after the first vaccination; in one patient after the second one. In 3 patients a biopsy for histopathological examinations was carried out. Results were typical for PR. In all patients laboratory examinations were within normal ranges. All patients were treated with cetirizine. Complete remission was observed within 14-30 days. Four patients were subjected to the second vaccination, but no skin lesions appeared. All patients are currently in good general health. It is possible that a relationship between anti- Sars-CoV-2 vaccination and PR/PRLE exists; however, it is very rare, in consideration of millions of vaccinated subjects and the low number of reported cases of PR/PRLE. The pathogenesis of this relationship is unknown. However, some hypotheses may be advanced: PR/PRLE following anti-Sars-CoV-2 vaccination may be just a coincidence; anti-Sars-CoV-2 vaccines cause a reactivation of HHV-6 and/or HHV-7; vaccines can induce a delayed hypersensitivity response clinically similar to drug-induced PRLE.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 1","pages":"9503"},"PeriodicalIF":1.1,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/ff/dr-15-1-9503.PMC10099291.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9371266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists.","authors":"Calogero Pagliarello,&nbsp;Carlo Renè Girardelli,&nbsp;Ignazio Stanganelli","doi":"10.4081/dr.2022.9534","DOIUrl":"https://doi.org/10.4081/dr.2022.9534","url":null,"abstract":"<p><p>Because of its higher level of safety compared to its parent medicine, thalidomide, lenalidomide (L) is chosen for the treatment of multiple myeloma. We report a patient who, within a month of using L, developed more than 10 basal cell carcinomas.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 1","pages":"9534"},"PeriodicalIF":1.1,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/f8/dr-15-1-9534.PMC10099294.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9371272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maculopapular sarcoidosis: the importance of skin signs.","authors":"Giovanna Galdo,&nbsp;Gelsomina Luongo,&nbsp;Daniela Capacchione,&nbsp;Damiano Abeni,&nbsp;Marta Grimaldi,&nbsp;Luca Fania","doi":"10.4081/dr.2022.9561","DOIUrl":"https://doi.org/10.4081/dr.2022.9561","url":null,"abstract":"<p><p>Sarcoidosis is a multisystem disease that affects the skin in 20 to 30% of cases. Skin findings are often the initial presenting signs, and cutaneous sarcoidosis may appear with a wide variety of lesions; it is often considered an imitator of many other skin diseases. Clinical appearance and specific dermoscopic criteria, confirmed by a typical pathology, may guide to the correct diagnosis. We report the case of a man affected by maculo-papular sarcoidosis on the back, in which the detection of cutaneous lesions was the initial step to determine the systemic nature of the disease.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 1","pages":"9561"},"PeriodicalIF":1.1,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/a2/dr-15-1-9561.PMC10086543.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9310691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of angiomatoid Spitz Nevus in the elderly, with clinical and dermoscopic features.","authors":"Gelsomina Luongo,&nbsp;Noè De Stefano,&nbsp;Antonio Perasole,&nbsp;Cesare Massone,&nbsp;Giovanna Galdo","doi":"10.4081/dr.2023.9669","DOIUrl":"https://doi.org/10.4081/dr.2023.9669","url":null,"abstract":"This case was presented at the on-line telepathology meeting on the ADOI platform held on October 19th 2022 by Dr Luongo.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 1","pages":"9669"},"PeriodicalIF":1.1,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/65/1c/dr-15-1-9669.PMC10099962.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9371270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammatory markers in psoriasis: a case-control study.","authors":"Hao Trong Nguyen,&nbsp;Long Dinh Hoang Vo,&nbsp;Nguyen Nhat Pham","doi":"10.4081/dr.2022.9516","DOIUrl":"https://doi.org/10.4081/dr.2022.9516","url":null,"abstract":"<p><p>Our case-control study of 60 patients with psoriasis vulgaris (PsV), 20 patients with psoriatic arthritis (PsA), and 34 healthy control participants in Ho Chi Minh City Hospital of Dermato-Venereology from October 2019 to September 2020 aimed to evaluate the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and associated factors in patients with PsV and PsA. Results showed that in the PsV group, significant correlations of NLR with Psoriasis Area and Severity Index and the high-sensitivity C-reactive protein (hs-CRP) level was noted (r=0.374 and r=0.352, respectively; P=0.003 and P=0.006, respectively). NLR was also related to PsA (P=0.007, OR=1.57). The area under the curve (AUC) for NLR in predicting PsA was 0.7554 (cut-off, 2.239; sensitivity, 85%; specificity, 61.67%). PLR was also related to PsA (P=0.008, OR=1.01). The AUC for PLR was 0.6513 (cut-off, 159.6; sensitivity, 55%; specificity, 88.33%). Thus, complete blood count parameters can reflect the inflammatory status of patients with PsV and PsA. NLR and PLR may be potential diagnostic markers for PsA in patients with psoriasis. Future studies should aim to assess the value and usage of these parameters.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 1","pages":"9516"},"PeriodicalIF":1.1,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/3d/dr-15-1-9516.PMC10099295.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9371268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The anxiety and depression disorder in adults with atopic dermatitis: experience of a dermatology hospital.","authors":"Ngo Minh Vinh,&nbsp;Vu Thi Thuy Trang,&nbsp;Luong Nguyen Dac Thuy,&nbsp;Huynh Thi Xuan Tam,&nbsp;Le Thi Thuy Hang,&nbsp;Pham Van Bac","doi":"10.4081/dr.2022.9524","DOIUrl":"https://doi.org/10.4081/dr.2022.9524","url":null,"abstract":"<p><p>The objectives of this study are to identify the proportion of atopic dermatitis adult patients having anxiety and depression disorder and to measure the relationship between anxiety and depression disorder and characteristics of atopic dermatitis. A cross-sectional study with convenience sampling was conducted. Diagnostic criteria for atopic dermatitis were based on modified Hanifin and Raijka criteria and the severity of anxiety-depression disorder was evaluated using the hospital anxiety and depression scale. In this study, 208 patients were enrolled. The percentage of patients with anxiety and subthreshold anxiety were 11.1% and 34.1%, respectively. 5.3% of patients had depression and 39.4% of patients suffered from subthreshold depression. The proportion of patients with mixed anxiety-depressive disorder was 1.44%. Patients with severe atopic dermatitis were more likely to endure anxiety but not depression. Allergies or autoimmune diseases and scoring atopic dermatitis C were two independent risk factors of depression whereas edema and excoriation were two independent risk factors related to anxiety in atopic dermatitis patients. These findings suggest that atopic dermatitis is associated with anxiety and depression. Allergies, autoimmune diseases, pruritus, and insomnia had a correlation with anxiety and depression disorder.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 1","pages":"9524"},"PeriodicalIF":1.1,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/d1/dr-15-1-9524.PMC10080285.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9282795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of autologous serum therapy in positive and negative autologous serum skin test patients in chronic urticaria in a tertiary care centre.","authors":"Raghavendra Kr,&nbsp;Bangaru H","doi":"10.4081/dr.2022.9525","DOIUrl":"https://doi.org/10.4081/dr.2022.9525","url":null,"abstract":"<p><p>Autologous serum therapy (AST) has been a recent therapeutic choice for a variety of chronic diseases such as allergic, inflammatory, infectious, and autoimmune disorders. However, evidence were not convincing of the beneficial effects of autologous serum therapy in treatment of Chronic urticaria (CU). CU is a common dermatological condition that is very disturbing to the patient as well as to the physician. A new observation was made about the abnormal type 1 reactions to intradermal autologous serum injections in some CU patients. This has led to the new subgroup of <i>autoimmune chronic urticaria.</i> The autologous serum skin test (ASST) is an intradermal test result in immediate hypersensitivity-type skin reactions in a subpopulation of CU patients and it's giving promising evidence of therapeutic and diagnostic benefit. Autologous whole blood injection has already been used as one of the old treatment modalities for chronic urticaria. The objectives of this study/reasearch are to analyse the efficacy of autologous serum therapy in patients with chronic urticaria and compare its results in ASST(+) and ASST(-) chronic urticaria patients. Approximately 5 mL of patients' blood was drawn in a plain vacutainer and centrifuged at 3000 r.p.m. for 10 min, separated 2.5 mL serum injected deep intramuscularly into gluteus muscle. Injections were repeated every week for about 9 weeks and a repeat follow up at 20 weeks was done. Out of a total of 20 patients, excellent improvement in terms of decrease in Urticaria assessment severity score was seen in 6 patients; whereas, 10 patients showed partial response, 2 patients showed no response and 2 patients lost the follow up. 10 patients with ASST(+) and 6 patients of ASST(-) showed little improvement in urticaria severity score. AST therapy is a cost-effective adjuvant modality to reduce the severity of symptoms of chronic urticaria. In some patients it's giving long term remission period and it decreases the updosing of antihistamines.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 1","pages":"9525"},"PeriodicalIF":1.1,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/ce/dr-15-1-9525.PMC10080287.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9282796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged impact of COVID-19 pandemic on delayed melanoma diagnosis: further data based on one-year appraisal from Italy.","authors":"Calogero Pagliarello,&nbsp;Mariacristina Sicher,&nbsp;Carlo Renè Girardelli,&nbsp;Ignazio Stanganelli","doi":"10.4081/dr.2022.9535","DOIUrl":"https://doi.org/10.4081/dr.2022.9535","url":null,"abstract":"Not available","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 1","pages":"9535"},"PeriodicalIF":1.1,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/44/e1/dr-15-1-9535.PMC10080289.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9641668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous metastases different clinical presentations: case series and review of the literature.","authors":"Icim Komurcugil,&nbsp;Zulkuf Arslan,&nbsp;Zulal Inci Bal,&nbsp;Mert Aydogan,&nbsp;Yagmur Ciman","doi":"10.4081/dr.2022.9553","DOIUrl":"https://doi.org/10.4081/dr.2022.9553","url":null,"abstract":"<p><p>Cutaneous metastasis (CM) is a rare clinical entity with an incidence of less than 10% among oncology patients. Dissemination to the skin can be via bloodstream, lymphatics, direct expansion or by seeding after surgical procedures. Skin metastases usually develop months to years after the diagnosis of the primary tumor, while it may be the opposite in some rare cases. CM has various clinical presentations; diagnoses can be easily overseen as CM can mimic other dermatologic diseases. Herein, we present five different cutaneous metastasis cases, each with distinct dermatological presentation. Our main aim here is to allow dermatologists to consider skin metastases in the differential diagnoses of dermatological diseases, in their clinical practice.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 1","pages":"9553"},"PeriodicalIF":1.1,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/05/dr-15-1-9553.PMC10080284.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9282792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mohs micrographic surgery: the experience of the dermatology unit of the university of Milan confirms the superiority over traditional surgery in high-risk non-melanoma skin cancers.","authors":"Gianluca Nazzaro,&nbsp;Anna Minuti,&nbsp;Eleonora Quattri,&nbsp;Emanuela Passoni","doi":"10.4081/dr.2022.9532","DOIUrl":"https://doi.org/10.4081/dr.2022.9532","url":null,"abstract":"<p><p>The constant increase in the incidence of non-melanoma skin cancers (NMSC) makes their treatment a topic of paramount interest. Because most NMSC tend to develop in visible areas such as the headneck area, it is a priority to choose the less destructive therapy and more appropriate reconstructive technique. Mohs Micrographic Surgery (MMS) represents the treatment of choice for skin tumors in critical sites, recurrent tumors and tumors with aggressive histologic features. We collected patients affected by NMSC who underwent MMS at the Dermatology Unit of IRCCS Fondazione Ca' Granda, Milan, in the period March 2017-December 2021. One hundred and fifty-nine patients were enrolled in this retrospective observational study. The excision margins were chosen based on a dermoscopic evaluation. The main histological diagnoses were basal cell carcinoma (145, 91.2%) and squamous cell carcinoma (10, 6.3%), in areas with high functional or anatomical value. 121 out of 159 surgeries did not require further enlargement after the removal of the clinically and dermoscopically visible lesion, but in 38 cases (23.9% of cases) the pathologist required at least one subsequent enlargement, due to the persistence of neoplasm at the bottom or at the margins of the lesion. Only one recurrence has been reported so far. MMS is a pathology-controlled surgery with high intrinsic value because of the low risk of recurrences and should be routinely adopted for high-risk NMSC.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 1","pages":"9532"},"PeriodicalIF":1.1,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/26/0f/dr-15-1-9532.PMC10099289.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9371267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}